Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Postgrad Med J. 2008 Nov;84(997):590-8. doi: 10.1136/hrt.2007.125401. Review.

PMID:
19103817
2.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
3.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
4.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
5.

Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.

Hausenloy DJ, Yellon DM.

Curr Opin Cardiol. 2009 Sep;24(5):473-82. doi: 10.1097/HCO.0b013e32832ebfe7. Review.

PMID:
19574922
7.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Review.

PMID:
23932901
8.
9.
11.
12.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
13.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
14.

The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.

Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA.

Rev Cardiovasc Med. 2008 Fall;9(4):239-58. Review.

PMID:
19122582
15.
16.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
17.

[New trends in lipidology: the increasing role of HDL-cholesterol].

Paragh G, Harangi M, László M.

Orv Hetil. 2008 Jul 27;149(30):1395-404. doi: 10.1556/OH.2008.28405. Review. Hungarian.

PMID:
18621598
18.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
19.

Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.

Pirillo A, Norata GD, Catapano AL.

Curr Pharm Des. 2013;19(21):3841-57. Review.

PMID:
23286430
Items per page

Supplemental Content

Support Center